10 Aug, 2020 RNAi Roundtable: Lumasiran, in Development for the Treatment of Primary Hyperoxaluria Type 1
On August 10, 2020, we hosted an online RNAi Roundtable to review progress with lumasiran, an RNAi therapeutic in development for the treatment of primary hyperoxaluria type 1.
Pritesh Gandhi, PharmD.
Vice President & General Manager, Lumasiran
Michael J.G. Somers, M.D.
Associate Chief and Gunnar B. Stickler Chair in Pediatric Nephrology, Division of Nephrology and Medical Director, Renal Dialysis Unit, Boston Children’s Hospital; Associate Professor of Pediatrics, Harvard Medical School; President, American Society of Pediatric Nephrology
Tracy McGregor, M.D.
Senior Director, Clinical Research